Behice KURTARAN, Semra PAYDAŞ, Aslıhan CANDEVİR, Sinan YAVUZ, Ayşe Sezai İNAL

Anti-CD20 antikor-rituksimab ve infeksiyon ilişkisi: Bir olgu nedeniyle

Son yıllarda literatürde anti-CD20 antikoru (rituksimab) tedavisi sonrası gelişen ciddi viral, mikobakteriyel ve fungal infeksiyonlar bildirilmektedir. Şimdiye kadar rituksimab ilişkili panoftalmit bildirilmemiş olup, CHOP-R tedavisi alan lenfomalı bir olguda ölümle sonlanan panoftalmit tablosu nedeni ile konuya dikkat çekilmesi ve rituksimab tedavileri ile infeksiyon ilişkisinin değerlendirilmesi amaçlanmıştır.

Anahtar Kelimeler:

Panoftalmit, Antijenler, CD20, Ölümle sonuçlanma, Yaşlı, Kadın, Lenfom, B-hücreli

Association of anti-CD20 antibody-rituximab and infection: A case report

In recent years, serious viral, mycobacterial and fungal infection cases which developed after anti-CD20 antibodies (rituximab) have been published. Upto now there was no panophtalmitis case associated with rituximab. In this paper we aimed to evaluate the relationship between rituximab treatments and infections, and attract attention to the issue with a panophtalmitis case with lymphoma who was on CHOP-R treatment and ended up with death.

Keywords:

Panophthalmitis, Antigens, CD20, Fatal Outcome, Aged, Female, Lymphoma, B-Cell,

PDF

___

1. Aksoy S, Harputluoglu H, Kilickap S et al: Rituximab- related viral infections in lymphoma patients, Leuk Lymphoma 2007;48(7):1307-12.
2. Archimbaud C, Bailly JL, Chambon M, Tournilhac O, Travade Peique-Lafeuille HP: Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000, J Clin Microbiol 2003;41(10):4605-10.
3. Cabanillas F, Liboy I, Pavia O, Rivera E: High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication, Ann Oncol 2006;17(9):1424-7.
4. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D: Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67(3):283-7.
5. Cattaneo C, Spedini P, Casari S et al: Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments, Leuk Lymphoma 2006;47(6):1013-7.
6. Coiffier B, Lepage E, Briere J et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med 2002;346(4):235-42.
7. Coiffier B, Salles G, Pfreundschuh M, Loeffler M: Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma, Blood 2004;104(5):1584-5.
8. Czuczman MS, Koryzna A, Mohr A et al: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma, J Clin Oncol 2005;23(4):694-704.
9. Feugier P, Van Hoof A, Sebban C et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte, J Clin Oncol 2005;23(18):4117-26.
10. Habermann TM, Weller EA, Morrison VA et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma, J Clin Oncol 2006;24(19):3121-7.
11. Hiddemann W, Kneba M, Dreyling M et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advancedstage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood 2005;106(12):3725-32.
12. Lenz G, Dreyling M, Hoster E et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG), J Clin Oncol 2005;23(9):1984-92.
13. Lin PC, Hsiao LT, Poh SB et al: Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP, Ann Hematol 2007;86(2):95-100.
14. McLaughlin P: Late-onset neutropenia following rituximab, Leuk Lymphoma 2006;47(6):965-6.
15. McLaughlin P, Grillo-Lopez A, Link B et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program, J Clin Oncol 1998;16(8):2825-33.
16. Micallef NM, Kahl BS, Maurer MJ et al: A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large Bcell lymphoma, Cancer 2006;107(12):2826-32.
17. Pfreundschuh M, Trumper L, Osterborg A et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group, Lancet Oncol 2006;7(5):379-91.
18. Quartier P, Tournilhac O, Archimbaud C et al: Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment, Clin Infect Dis 2003;36(3):47-9.
19. Tam CS, Seymour JF, Brown M et al: Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies, Haematologica 2005;90(5):700-2.
20. Tsutsumi Y, Kanamori H, Mori A et al: Reactivation of hepatitis B virus with rituximab, Expert Opin Drug Saf 2005;4(3):599-608.
21. Zinzani P: A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first line treatment in patients with follicular lymphoma, Blood 2001;98:842a (Abstr 3500).